POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER

Aim. To study the efficacy of ivabradine in the prevention of cardiotoxic effects due to chemotherapeutic drugs in patients with breast cancer. Material and methods. The open randomized uncontrolled study included 55 patients with breast cancer who had to undergo chemotherapy by anthracyclines. The inclusion criterion was a heart rate >70 beats/min. Collection of complaints and anamnesis, ECG, echocardiography, routine laboratory tests were performed in all patients initially and after 1, 3, 6 and 12 months. All patients were treated with polychemotherapy with anthracyclines in combination with cyclophosphamide and fluorouracil. The patients included into the study were randomized into two groups. Patients of the main group (n=23) were additionally prescribed ivabradine in a daily dose of 10 mg followed by a dose titration. Patients of the control group (n=32) received only polychemotherapy. Results. In the main group a decrease in heart rate was observed already by the first month (from 83.6±9.5 to 67.1±7.5 beats/min, p<0.001) and persisted until the 6th month (74.2±14.9 beats/min, p<0.001). In the main group, the frequency of complaints of palpitation significantly decreased by the 1st month of treatment (from 60.9% to 30%, p=0.05) with a slight increase in further observation. A significant increase in the left atrium diameter (from 35.0±4.0 to 35.9±3.9 cm; p=0.009), the left atrium volume (from 42.0±12.8 to 43.7±11.6 ml; p=0.02), the end diastolic left ventricle (LV) volume (from 81.5±16.5 to 88.8±16.5 ml, p=0.007) and the end systolic LV volume (from 30.7±8.1 to 32.3±6.2 ml; p=0.01) were found in the main group in a month after polychemotherapy. Dynamics of the main echocardiographic indices was similar in the control group. By 6 months of observation the indexed mass of LV myocardium significantly increased in the control group (from 66.9±14.6 to 74.3±19.0 g/m²; p=0.024) in the absence of that in the main group (from 65.4±15.2 to 70.7±11.3 g/m²; p>0.05). A significant change in the LV ejection fraction was not found in both groups. Significant differences in LV global longitudinal strain were found between groups in 1, 3 and 6 months of observation (p<0.05), but after 12 months the groups were comparable in longitudinal strain values. Conclusion. Ivabradine therapy in patients with breast cancer and heart rate >70 beats/min was safe and did not cause bradycardia. Ivabradine use was accompanied by a significant reduction in a number of patients with complaints of palpitation, contributed to the preservation of normalLV global longitudinal deformation in chemotherapy, while the control group had negative changes with a maximum by the 6th month of follow-up.

1. Zamorano J.L., Lancellotti P., Rodriguez MuЦoz D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancertreatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801.

2. Vasyuk Y.A. Shkolnik E.L., Nesvetov V.V., et al. Cardio-oncology: modern aspects of diagnosis of cardiovascular complications in antitumor therapy. Serdechnaya Nedostatochnost'. 2016;17(6):383-7. (In Russ.) [Васюк Ю.А..,Школьник Е.Л., Несветов В.В.,Школьник Л.Д.., Селезнева М.Г. Кардиоонкология: современные аспекты диагностики сердечно-сосудистых осложнений при противоопухолевой терапии. Сердечная Недостаточность. 2016;17(6):383-7]

3. Vasyuk Y.A. Shkolnik E.L., Nesvetov V.V., et al. Cardiooncology: modern aspects of the prevention of anthracycline cardiotoxicity. Kardiologiia. 2016;56(12):72-9. (In Russ.) [Васюк Ю.А., Школьник Е.Л., Несветов В.В., и др. Кардиоонкология: современные аспекты профилактики антрациклиновой кардиотоксиности. Кардиология. 2016;56(12):72-9]

4. Aminkeng F., Ross C.J., Rassekh S.R., et al. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017. doi: 10.1111/bcp.13218. [Epub ahead of print].

5. Rose-Felker K., Border W.L., Hong B.J., Chow E.J. Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction. Heart Fail Clin. 2017;13(2):311-25.

6. Narayan H.K., Wei W., Feng Z., et al. Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart. 2017;4(1):e000524.

7. Kistler K.D., Kalman J., Sahni G., et al. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study. Clin Lymphoma Myeloma Leuk. 2017;17(2):89-96.e3.

8. Gendlin G.E.,Storojakov G.I.,Shuikova K.V. Acute cardiovascular events during use of anticancer chemotherapeutic agents: clinical observations. Klinicheskaya Onkogematologiya. 2011;4(2):155-64. (In Russ.) [Гендлин Г.Е., Сторожаков Г. И., Шуйкова К.В. Острые сердечно-сосудистые события во время применения противоопухолевых химиопрепаратов: клинические наблюдения. Клиническая Онкогематология. 2011;4(2):155-64]

9. Ershov V.I., Litvitsky P.F., Kochkareva Yu.B. Free radical peroxide processes and cardiotoxicity in the treatment of malignant lymphomas. Klinicheskaya Meditsina. 2006;84(9):47-51. (In Russ.) [Ершов В.И., Литвицкий П.Ф., Кочкарева Ю.Б. Свободно радикальные перекисные процессы и кардиотоксичность при лечении злокачественных лимфом. Клиническая Медицина. 2006;84(9):47-51]

10. Minotti G., Menna P., Salvatorelli E., et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229].

11. Vergely C., Delemasure S., Cottin Y., Rochette L. Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab. 2007;35:1-7.

12. Tallaj J.A., Franco V., Rayburn B.K., et al. Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. J Heart Lung Transplant. 2005;24:2196-201.

13. Vasyuk Y.A. Shkolnik E.L., Nesvetov V.V., et al. Myocardial metabolic background on chemotherapy and means of their correction CardioSomatika. 2013;4:20-4. (In Russ.) [Васюк Ю.А, Школьник.Е.Л., Несветов В.В., и др. Нарушения метаболизма миокарда на фоне химиотерапевтического лечения, а также возможности их коррекции. CardioСоматика. 2013;4:20-4].

14. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy. JACC. 2010;55(3):213-20.

15. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.

16. Kaya M.G., Ozkan M., Gunebakmaz O., et al. Protective effects of nebivolol against anthracyclineinduced cardiomyopathy: A randomized control study. Int J Cardiol. 2013;167(5):2306-10.

17. El-Shitany N.A., Tolba O.A., El-Shanshory M.R., El-Hawary E.E. Protective effect of carvedilol on adriamycininduced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18(8):607-13.

18. Cardinale D., Colombo A., Sandri M.T. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-8.

19. Ovchinnikov E.G., Kleymenteva T.P. The problem of prevention of associated cardiovascular disease in cancer patients during chemotherapy. Meditsinskiy Al'manakh. 2014;3:159-61. (In Russ.) [Овчинникова Е.Г., Клейментьева Т.П. Проблема профилактики ассоциированной сердечно-сосудистой патологии у онкологических больных в процессе проведения химиотерапии. Медицинский Альманах. 2014;3:159-61].

20. Georgakopoulos P., Roussou P., Matsakas E. Cardioprotective effect of metoprolol and enalapril in doxorubicintreated lymphoma patients: A prospective, parallel group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894-6.

21. Zhang J., Cui X., Yan Y., et al. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res. 2016;8(7):2862-75.

22. Gulati G., Heck S.L., Ree A.H., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 .2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671-80.

23. Lenneman A.J., Wang L., Wigger M, et al. Heart Transplant Survival Outcomes for Adriamycin Dilated Cardiomyopathy. Am J Cardiol. 2013;111(4):609-12.

24. Rickard J., Kumbhani D.J., Baranowski B., et al. Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. Am J Cardiol. 2010;105(4):522-6.

25. Brown H.F., , DiFrancesco D., Noble S.J. How does adrenaline accelerate the heart? Nature 1979;280:235-6.

26. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular dysfunction and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-9.

27. Colak M.C., Parlakpinar H., Tasdemir S., et al. Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol. 2012;31(9):945-54.

28. Reshina I.V., Kalyagin A.N., Sereda N.N. Application of ivabradine for the purpose of arresting cardiotoxic effects in patients with oncological diseases receiving polychemotherapy. Consilium Medicum. 2010;12(5):110-113. (In Russ.) [Решина И.В., Калягин А.Н., Середа Н.Н. Применение ивабрадина с целью купирования кардиотоксических эффектов у больных онкологическими заболеваниями, получающих полихимиотерапию. Consilium Medicum. 2010;12(5):110-3].